Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine

M. D. Young, D. L. Schneider, A. J. Zuckerman, W. Du, B. Dickson, W. C. Maddrey

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Present hepatitis B vaccines use multidose prolonged regimens, which even healthcare workers at risk do not always complete. Moreover, when vaccination is completed there remain some who fail to achieve adequate protection. The protection of adults at risk could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Vaccine-naive adults were randomized to vaccination with either Engerix-B (SmithKline Biologicals, Rixensart, Belgium) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK). The primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 ± 2 weeks) after beginning vaccination. A total of 304 adults entered the study. Of these, 16 failed to complete the study (9 on Hepacare and 7 on Engerix-B). With the Engerix-B standard (0, 1, 6) regimen, 88% of subjects were protected by month 7, whereas with the triple antigen vaccine a 2-dose regimen (0, 1) provided equivalent protection (91%) within 6 months and a 3-dose (0, 1, 6) regimen was significantly superior (98% seroprotected by 7 months after starting vaccination P < .001). With adults at risk for a suboptimal response (i.e., older adults, the obese, men, and smokers) the triple antigen vaccine produced a greater degree of protection. The vaccines had similar safety profiles. Both vaccines were well tolerated. In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens produced an enhanced immunologic response and was as effective as a 2-and 3-dose regimen.

Original languageEnglish (US)
Pages (from-to)372-376
Number of pages5
JournalHepatology
Volume34
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Synthetic Vaccines
Hepatitis B
Vaccination
Vaccines
Antigens
Hepatitis B Vaccines
Belgium
Delivery of Health Care
Safety
Engerix-B

ASJC Scopus subject areas

  • Hepatology

Cite this

Young, M. D., Schneider, D. L., Zuckerman, A. J., Du, W., Dickson, B., & Maddrey, W. C. (2001). Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology, 34(2), 372-376. https://doi.org/10.1053/jhep.2001.26167

Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. / Young, M. D.; Schneider, D. L.; Zuckerman, A. J.; Du, W.; Dickson, B.; Maddrey, W. C.

In: Hepatology, Vol. 34, No. 2, 2001, p. 372-376.

Research output: Contribution to journalArticle

Young, MD, Schneider, DL, Zuckerman, AJ, Du, W, Dickson, B & Maddrey, WC 2001, 'Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine', Hepatology, vol. 34, no. 2, pp. 372-376. https://doi.org/10.1053/jhep.2001.26167
Young, M. D. ; Schneider, D. L. ; Zuckerman, A. J. ; Du, W. ; Dickson, B. ; Maddrey, W. C. / Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. In: Hepatology. 2001 ; Vol. 34, No. 2. pp. 372-376.
@article{cc980abfe4d14f288abe554f8677638b,
title = "Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine",
abstract = "Present hepatitis B vaccines use multidose prolonged regimens, which even healthcare workers at risk do not always complete. Moreover, when vaccination is completed there remain some who fail to achieve adequate protection. The protection of adults at risk could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Vaccine-naive adults were randomized to vaccination with either Engerix-B (SmithKline Biologicals, Rixensart, Belgium) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK). The primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 ± 2 weeks) after beginning vaccination. A total of 304 adults entered the study. Of these, 16 failed to complete the study (9 on Hepacare and 7 on Engerix-B). With the Engerix-B standard (0, 1, 6) regimen, 88{\%} of subjects were protected by month 7, whereas with the triple antigen vaccine a 2-dose regimen (0, 1) provided equivalent protection (91{\%}) within 6 months and a 3-dose (0, 1, 6) regimen was significantly superior (98{\%} seroprotected by 7 months after starting vaccination P < .001). With adults at risk for a suboptimal response (i.e., older adults, the obese, men, and smokers) the triple antigen vaccine produced a greater degree of protection. The vaccines had similar safety profiles. Both vaccines were well tolerated. In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens produced an enhanced immunologic response and was as effective as a 2-and 3-dose regimen.",
author = "Young, {M. D.} and Schneider, {D. L.} and Zuckerman, {A. J.} and W. Du and B. Dickson and Maddrey, {W. C.}",
year = "2001",
doi = "10.1053/jhep.2001.26167",
language = "English (US)",
volume = "34",
pages = "372--376",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine

AU - Young, M. D.

AU - Schneider, D. L.

AU - Zuckerman, A. J.

AU - Du, W.

AU - Dickson, B.

AU - Maddrey, W. C.

PY - 2001

Y1 - 2001

N2 - Present hepatitis B vaccines use multidose prolonged regimens, which even healthcare workers at risk do not always complete. Moreover, when vaccination is completed there remain some who fail to achieve adequate protection. The protection of adults at risk could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Vaccine-naive adults were randomized to vaccination with either Engerix-B (SmithKline Biologicals, Rixensart, Belgium) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK). The primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 ± 2 weeks) after beginning vaccination. A total of 304 adults entered the study. Of these, 16 failed to complete the study (9 on Hepacare and 7 on Engerix-B). With the Engerix-B standard (0, 1, 6) regimen, 88% of subjects were protected by month 7, whereas with the triple antigen vaccine a 2-dose regimen (0, 1) provided equivalent protection (91%) within 6 months and a 3-dose (0, 1, 6) regimen was significantly superior (98% seroprotected by 7 months after starting vaccination P < .001). With adults at risk for a suboptimal response (i.e., older adults, the obese, men, and smokers) the triple antigen vaccine produced a greater degree of protection. The vaccines had similar safety profiles. Both vaccines were well tolerated. In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens produced an enhanced immunologic response and was as effective as a 2-and 3-dose regimen.

AB - Present hepatitis B vaccines use multidose prolonged regimens, which even healthcare workers at risk do not always complete. Moreover, when vaccination is completed there remain some who fail to achieve adequate protection. The protection of adults at risk could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Vaccine-naive adults were randomized to vaccination with either Engerix-B (SmithKline Biologicals, Rixensart, Belgium) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK). The primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 ± 2 weeks) after beginning vaccination. A total of 304 adults entered the study. Of these, 16 failed to complete the study (9 on Hepacare and 7 on Engerix-B). With the Engerix-B standard (0, 1, 6) regimen, 88% of subjects were protected by month 7, whereas with the triple antigen vaccine a 2-dose regimen (0, 1) provided equivalent protection (91%) within 6 months and a 3-dose (0, 1, 6) regimen was significantly superior (98% seroprotected by 7 months after starting vaccination P < .001). With adults at risk for a suboptimal response (i.e., older adults, the obese, men, and smokers) the triple antigen vaccine produced a greater degree of protection. The vaccines had similar safety profiles. Both vaccines were well tolerated. In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens produced an enhanced immunologic response and was as effective as a 2-and 3-dose regimen.

UR - http://www.scopus.com/inward/record.url?scp=0034920759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034920759&partnerID=8YFLogxK

U2 - 10.1053/jhep.2001.26167

DO - 10.1053/jhep.2001.26167

M3 - Article

C2 - 11481622

AN - SCOPUS:0034920759

VL - 34

SP - 372

EP - 376

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -